Using semaglutide to treat psoriasis in obese patients
Effect of Semaglutide in Patients With Psoriasis and Obesity
This study is testing if the weight loss drug semaglutide can help improve psoriasis symptoms in adults who are both obese and have psoriasis.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 14 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06937060 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of semaglutide, a glucagon-like peptide-1 receptor agonist, on patients suffering from psoriasis and obesity. The study aims to determine whether weight loss achieved through semaglutide can lead to improvements in psoriasis severity and overall disease management. Eligible participants include adults aged 18 to 75 with a clinical diagnosis of psoriasis and a body mass index indicating obesity or overweight. The trial will monitor the efficacy of semaglutide in reducing psoriasis symptoms while addressing weight-related health issues.
Who should consider this trial
Good fit: Ideal candidates are Chinese adults aged 18 to 75 with moderate to severe psoriasis and obesity or overweight.
Not a fit: Patients with type 1 diabetes, a history of pancreatitis, or contraindications to GLP1 RA will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve psoriasis symptoms and overall health in obese patients.
How similar studies have performed: Previous studies have shown the efficacy of older GLP1 RAs in improving psoriatic disease activity, but trials specifically on semaglutide for this purpose are novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * a clinical diagnosed Psoriatic disease of at least 6 months before signing of informed consent. * Women who are sexually active and not postmenopausal, agreement to remain abstinent or use 2 effective methods of contraception * \>18 years of age, up to 75 years of age * Adult with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) * Moderate to severe psoriasis (PASI score 5-10= moderate, \>10 = severe) * Chinese ethnicity * On stable dose of standard treatment * Ability to comply with stud Exclusion Criteria: * Patients who refuse to give consent * Contraindication to use of GLP1 RA * History of pancreatitis * History of MEN / MTC * Known hypersensitivity to semaglutide or excipients in semaglutide * Type 1 diabetes * Gallbladder disease * Active malignancy or History of malignancy within 5 years * Active chronic or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals within 4 weeks before baseline visit * Pregnancy or breastfeeding, subjects should inform their healthcare provider of a known or suspected pregnancy * History of allergic reaction assessed as related to investigational product by the investigator * Major psychiatric illness * Treatment with live/ attenuated vaccine within the last 28 days prior to randomisation * History of alcohol or substance abuse within 6 months prior to initial screening * Patients with a history of suicidal attempts or active suicidal ideation
Where this trial is running
Hong Kong
- The University of Hong Kong, Department of Medicine — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Man Ho Martin Chung — The University of Hong Kong
- Study coordinator: Man Ho Martin Chung
- Email: drcmhm@hku.hk
- Phone: 22553111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.